Abstract
Background Antibodies are crucial for vaccine-mediated protection against many pathogens. Modifications to vaccine delivery that increase antibody magnitude, longevity, and/or quality are therefore of great interest for maximising efficacy. We have previously shown that a delayed fractional (DFx) dosing schedule (0-1-6mo) – using AS01B-adjuvanted RH5.1 malaria antigen – substantially improves serum IgG durability as compared to monthly dosing (0-1-2mo; NCT02927145). However, the underlying mechanism and whether there are wider immunological changes with DFx dosing was unclear.
Methods Immunokinetics of PfRH5-specific Ig across multiple isotypes were compared between DFx and monthly regimen vaccinees. Peak responses were characterised in-depth with a systems serology platform including biophysical and functional profiling. Computational modelling was used to define the humoral feature set associated with DFx dosing. PfRH5-specific B cells were quantified by flow cytometry and sorted for single cell RNA sequencing (scRNA-seq). Differential gene expression between DFx and monthly dosing regimens was explored with Seurat, DESeq2 and gene set enrichment analysis.
Results DFx dosing increases the frequency of circulating PfRH5-specific B cells and longevity of PfRH5-specific IgG1, as well as other isotypes and subclasses. At the peak antibody response, DFx dosing was distinguished by a systems serology feature set comprising increased FcRn-binding, IgG avidity, and proportion of G2B and G2S2F IgG Fc glycans, alongside decreased IgG3, antibody-dependent complement deposition, and proportion of G1S1F IgG Fc glycan. At the same time point, scRNA-seq of PfRH5-specific B cells revealed enriched plasma cell and Ig / protein export signals in the monthly dosing group as compared to DFx vaccinees.
Conclusions DFx dosing of the RH5.1/AS01B vaccine had a profound impact on the humoral response. Our data suggest plausible mechanisms relating to improved FcRn-binding (known to improve Ig longevity) and a potential shift from short-lived to long-lived plasma cells. Recent reports of the positive impact of delayed boosting on SARS-CoV-2 vaccine immunogenicity highlight the broad relevance of these data.
Competing Interest Statement
S.J.D. is a named inventor on patent applications relating to PfRH5 and/or other malaria vaccines and immunisation regimens. A.M.M. has an immediate family member who is listed as an inventor on patents relating to PfRH5 and/or other malaria vaccines and immunisation regimens. No other authors declare any potential conflicts of interest.
Funding Statement
C.M.N. was supported by a Sir Henry Wellcome Postdoctoral Fellowship (209200/Z/17/Z). S.J.D. was supported by a Wellcome Trust Senior Fellowship (106917/Z/15/Z). S.J.D. was also a Lister Institute Research Prize Fellow and a Jenner Investigator. The ChAd63-MVA trial (NCT02181088) was supported by funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the grant agreement for MultiMalVax (no. 305282). The protein/AS01B trial (NCT02927145) was funded by MRC grant MR/K025554/1 and the Office of Infectious Diseases, Bureau for Global Health, US Agency for International Development (USAID), under the terms of the Malaria Vaccine Development Program (MVDP) contract AID-OAA-C-15-00071, for which Leidos is the prime contractor. Both clinical studies were also supported in part by UK NIHR infrastructure through the NIHR Oxford Biomedical Research Centre. The Freiburg Galaxy Team at the University of Freiburg (Germany) is funded by the Collaborative Research Centre 992 Medical Epigenetics (DFG grant SFB 992/1 2012) and the German Federal Ministry of Education and Research BMBF grant 031 A538A de.NBI-RBC. The Galaxy server is in part funded by Collaborative Research Centre 992 Medical Epigenetics (DFG grant SFB 992/1 2012) and German Federal Ministry of Education and Research (BMBF grants 031 A538A/A538C RBC, 031L0101B/031L0101C de.NBI-epi, 031L0106 de.STAIR (de.NBI)).The opinions expressed herein are those of the authors and do not necessarily reflect the views of the US Agency for International Development. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical trial NCT029271452 from which samples were used for this study was approved by the Oxford Research Ethics Committee A in the UK (REC reference 16/SC/0345) as well as by the UK Medicines and Healthcare products Regulatory Agency (MHRA; reference 21584/0362/001-0001). All volunteers gave written informed consent. Data from an additional trial, NCT02181088 was also included in early analyses. This trial was also approved by the Oxford Research Ethics Committee A in the UK (REC references 14/SC/0120) as well as by the UK MHRA.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Carolyn Nielsen (carolyn.nielsen{at}bioch.ox.ac.uk). The scRNA-seq data generated during this study are available from the NCBI SRA database, BioProject accession number SUB10783850.
